Introduction
CJC-1295 is available in two forms that differ fundamentally in their pharmacokinetic profiles: CJC-1295 with DAC and CJC-1295 without DAC. Understanding the distinction between these two variants is essential for researchers selecting the appropriate compound for their study design. The difference hinges on a single chemical modification — the Drug Affinity Complex — that transforms a short-acting peptide into a long-acting one.
What Is the Drug Affinity Complex (DAC)?
The Drug Affinity Complex is a chemical modification added to CJC-1295 that allows the peptide to covalently bind to albumin in the bloodstream. Albumin is an abundant plasma protein with a long circulatory half-life of approximately 19 days. By binding to albumin, the DAC-modified peptide essentially hitchhikes on albumin’s long circulation time, dramatically extending its own half-life from approximately 30 minutes to 6 to 8 days.
CJC-1295 Without DAC
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) is a stabilized analogue of GHRH(1-29) with amino acid substitutions that protect against enzymatic degradation but without the albumin-binding modification. Its half-life of approximately 30 minutes means it produces a relatively brief elevation in GH following administration, more closely mimicking a natural GHRH pulse. This pulsatile kinetic profile makes it suitable for research protocols designed to study physiological-like GH release patterns.
CJC-1295 With DAC
The DAC version produces sustained, continuous elevation of GH and IGF-1 rather than a pulsatile pattern. Studies have shown that a single administration maintains elevated GH levels for days. This makes the DAC version useful for research protocols where sustained GH axis activation is the objective, such as chronic exposure studies, body composition research over extended periods, or IGF-1 elevation studies.
Research Implications of Kinetic Differences
The pulsatile vs continuous distinction is not merely pharmacokinetic — it has biological significance. Natural GH secretion is pulsatile, and some research suggests that pulsatile GH exposure produces different downstream effects than continuous exposure. For example, hepatic IGF-1 production and certain anabolic signaling patterns may differ between pulsatile and tonic GH stimulation. Researchers studying GH biology should select the variant whose kinetic profile matches their research hypothesis.
Practical Research Considerations
CJC-1295 without DAC requires more frequent administration to maintain GH axis stimulation in protocols requiring sustained effects, while the DAC version requires less frequent dosing for equivalent duration of action. For short-term or acute GH pulse studies, the non-DAC version is more appropriate. For chronic or sustained elevation studies, the DAC version is more practical.
Conclusion
CJC-1295 with and without DAC are not interchangeable research compounds. Their fundamentally different half-lives and GH release kinetics make each appropriate for different research designs. Selecting the correct variant requires clear understanding of whether the research objective requires pulsatile or sustained GH pathway activation.